TOKYO -- Japanese researchers from Keio University and elsewhere announced Thursday that they have begun a clinical trial on a gene therapy to restore light sensitivity in patients with retinitis ...

Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been ...

I'm A Celebrity fans have sparked a major debate over which of the final three stars deserves to win. Read more.

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...

A unique collaboration between electrical engineers and ophthalmologists solves clinical, computational challenges.

Two-year data with eyeDNA Therapeutics’ gene therapy for retinitis pigmentosa (RP), an inherited ... damage to light-detecting cells in the retina and is the leading cause of inheritable blindness.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office has issued a composition ...

Aurora Pharmaceutical is pleased to announce the availability of EquiCoxib, the FDA-approved generic equivalent of Equioxx® (firocoxib), a non-steroidal anti-inflammatory drug (NSAID) used for pain ...

Mr. Iwicki stated, “I am proud of the work we have done at KALA utilizing our MSC-S platform, and I am very excited about the potential of our lead product candidate, KPI-012 for the treatment of PCED ...

A report from Zhongshan Daily & Zhongshan International Communications Center: In July 2024, the elderly health care vouchers of Hong Kong could be used in Zhongshan Chenxinghai Hospital. Zhongshan ...

Focused on the path ahead October ? December 2024 Net sales increased by 3 percent to SEK 7,729m (7,532).Gross profit increased by 2 percent to SEK 2,582m (2,526).EBITDA declined by 63 percent to SEK ...